Methods for Treating Cardiac Valve Disease Using Pharmaceutical Compounds
Summary
The USPTO granted Patent US12599608B2 to The Regents of the University of California covering methods of treating cardiac valve disease, including calcific aortic valve disease (CAVD), by administering pharmaceutical compounds of Formulae I-X. The patent names Christina Theodoris and Deepak Srivastava as inventors and includes 4 claims covering therapeutic applications and compound identification methods.
What changed
The USPTO issued Patent US12599608B2 granting exclusive rights to methods of treating cardiac valve disease, specifically calcific aortic valve disease, using therapeutically effective amounts of compounds falling within Formulae I-X or their pharmaceutical salts, solvates, or prodrugs. The patent also covers methods for identifying candidate compounds for cardiac valve disease treatment.
For pharmaceutical companies, research institutions, and medical device manufacturers, this patent establishes intellectual property barriers in the cardiac valve disease treatment space. Parties developing competing therapies or diagnostic methods for CAVD should conduct freedom-to-operate analyses to assess potential infringement risks.
What to do next
- Review patent claims for freedom-to-operate implications
- Assess potential licensing opportunities
- Monitor for related patent family publications
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods for treating cardiac valve disease
Grant US12599608B2 Kind: B2 Apr 14, 2026
Assignee
The Regents of the University of California
Inventors
Christina Theodoris, Deepak Srivastava
Abstract
The present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
CPC Classifications
A61K 31/55 A61K 31/132 A61K 31/198 A61K 31/396 A61K 31/426 A61K 31/433 A61K 31/44 A61K 31/485 A61K 31/506 A61K 45/06 A61K 31/4035 A61K 31/4245 A61K 31/428 A61K 31/4453 A61K 31/635 A61P 9/10
Filing Date
2019-08-20
Application No.
17269623
Claims
4
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.